Nizatidinum [Latin]

Nizatidinum [Latin] Brand names, Nizatidinum [Latin] Analogs

Nizatidinum [Latin] Brand Names Mixture

No information avaliable

Nizatidinum [Latin] Chemical_Formula

C₁₂H₂₁N₅O₂S₂

Nizatidinum [Latin] RX_link

http://www.rxlist.com/cgi/generic/nizat.htm

Nizatidinum [Latin] fda sheet

Nizatidinum_[Latin] FDA

Nizatidinum [Latin] msds (material safety sheet)

Nizatidinum [Latin] Synthesis Reference

R. P. Pioch, U.S. Pat. 4,375,547 (1982)

Nizatidinum [Latin] Molecular Weight

331.46 g/mol

Nizatidinum [Latin] Melting Point

203 ^oC

Nizatidinum [Latin] H₂O Solubility

10-33mg/mL

Nizatidinum [Latin] State

Solid

Nizatidinum [Latin] LogP

1.506

Nizatidinum [Latin] Dosage Forms

Capsule (150, 300 mg)

Nizatidinum [Latin] Indication

For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, active benign gastric ulcer, and active duodenal ulcer.

Nizatidinum [Latin] Pharmacology

Nizatidine is a competitive, reversible inhibitor of histamine at the histamine H2-receptors, particularly those in the gastric parietal cells. By inhibiting the action of histamine on stomach cells, nizatidine reduces stomach acid production. Nizatidine had no demonstrable antiandrogenic action. Full-dose therapy for the problems treated by nizatidine lasts no longer than 8 weeks. It has been demonstrated that treatment with a reduced dose of nizatidine is effective as maintenance therapy following healing of active duodenal ulcers.

Nizatidinum [Latin] Absorption

Rapid (bioavailability of nizatidine exceeds 70%)

Nizatidinum [Latin] side effects and Toxicity

Oral, rat LD₅₀: 301 mg/kg. Symptoms of overdose include cholinergic-type effects including lacrimation, salivation, emesis, miosis, and diarrhea.

Nizatidinum [Latin] Patient Information

Nizatidinum [Latin] Organisms Affected

Humans and other mammals